Shopping Cart 0
Cart Subtotal
USD 0

Smoothened Homolog (Protein Gx or SMO)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500

Details

Smoothened Homolog (Protein Gx or SMO)-Pipeline Review, H2 2017

Summary

Smoothened Homolog (Protein Gx or SMO)-Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Respiratory and Undisclosed which include indications Basal Cell Carcinoma (Basal Cell Epithelioma), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Medulloblastoma, Cirrhosis, Esophageal Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Peritoneal Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO)-Pipeline Review, H2 2017, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)

The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects

The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smoothened Homolog (Protein Gx or SMO)-Overview

Smoothened Homolog (Protein Gx or SMO)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Smoothened Homolog (Protein Gx or SMO)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smoothened Homolog (Protein Gx or SMO)-Companies Involved in Therapeutics Development

BeiGene Ltd

F. Hoffmann-La Roche Ltd

Ignyta Inc

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

Pfizer Inc

Redx Pharma Plc

Sun Pharma Advanced Research Company Ltd

Smoothened Homolog (Protein Gx or SMO)-Drug Profiles

glasdegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSA-10-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-5471-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Smoothened Homolog for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sonidegib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoothened Homolog (Protein Gx or SMO)-Dormant Products

Smoothened Homolog (Protein Gx or SMO)-Discontinued Products

Smoothened Homolog (Protein Gx or SMO)-Product Development Milestones

Featured News & Press Releases

May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update

Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Nov 28, 2016: Curis Announces Full Approval of Roche's Erivedge in the European Union

Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial

Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial

Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting

Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS

Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial

Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment

Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients

Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting

May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer

Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by BeiGene Ltd, H2 2017

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Pipeline by Ignyta Inc, H2 2017

Pipeline by IMPACT Therapeutics Inc, H2 2017

Pipeline by Mayne Pharma Group Ltd, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Redx Pharma Plc, H2 2017

Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Smoothened Homolog (Protein Gx or SMO) Therapeutic Products under Development, Key Players in Smoothened Homolog (Protein Gx or SMO) Therapeutics, Smoothened Homolog (Protein Gx or SMO) Pipeline Overview, Smoothened Homolog (Protein Gx or SMO) Pipeline, Smoothened Homolog (Protein Gx or SMO) Pipeline Assessment


Companies

BeiGene Ltd

F. Hoffmann-La Roche Ltd

Ignyta Inc

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

Pfizer Inc

Redx Pharma Plc

Sun Pharma Advanced Research Company Ltd

Company Profile

Company Profile Title

Smoothened Homolog (Protein Gx or SMO)-Pipeline Review, H2 2017

Summary

Smoothened Homolog (Protein Gx or SMO)-Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Respiratory and Undisclosed which include indications Basal Cell Carcinoma (Basal Cell Epithelioma), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Medulloblastoma, Cirrhosis, Esophageal Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Peritoneal Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO)-Pipeline Review, H2 2017, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)

The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects

The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smoothened Homolog (Protein Gx or SMO)-Overview

Smoothened Homolog (Protein Gx or SMO)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Smoothened Homolog (Protein Gx or SMO)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smoothened Homolog (Protein Gx or SMO)-Companies Involved in Therapeutics Development

BeiGene Ltd

F. Hoffmann-La Roche Ltd

Ignyta Inc

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

Pfizer Inc

Redx Pharma Plc

Sun Pharma Advanced Research Company Ltd

Smoothened Homolog (Protein Gx or SMO)-Drug Profiles

glasdegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSA-10-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-5471-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Smoothened Homolog for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sonidegib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoothened Homolog (Protein Gx or SMO)-Dormant Products

Smoothened Homolog (Protein Gx or SMO)-Discontinued Products

Smoothened Homolog (Protein Gx or SMO)-Product Development Milestones

Featured News & Press Releases

May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update

Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Nov 28, 2016: Curis Announces Full Approval of Roche's Erivedge in the European Union

Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial

Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial

Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting

Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS

Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial

Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment

Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients

Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting

May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer

Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by BeiGene Ltd, H2 2017

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Pipeline by Ignyta Inc, H2 2017

Pipeline by IMPACT Therapeutics Inc, H2 2017

Pipeline by Mayne Pharma Group Ltd, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Redx Pharma Plc, H2 2017

Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Smoothened Homolog (Protein Gx or SMO) Therapeutic Products under Development, Key Players in Smoothened Homolog (Protein Gx or SMO) Therapeutics, Smoothened Homolog (Protein Gx or SMO) Pipeline Overview, Smoothened Homolog (Protein Gx or SMO) Pipeline, Smoothened Homolog (Protein Gx or SMO) Pipeline Assessment


Companies

BeiGene Ltd

F. Hoffmann-La Roche Ltd

Ignyta Inc

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

Pfizer Inc

Redx Pharma Plc

Sun Pharma Advanced Research Company Ltd